8-K: Crinetics Wins FDA Approval for Oral Acromegaly Drug PALSONIFY

Crinetics Pharmaceuticals announced FDA approval for PALSONIFY (paltusotine), the first once-daily, oral treatment for adults with acromegaly.

Summary

• The U.S. Food and Drug Administration (FDA) approved PALSONIFY™ (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
• PALSONIFY, a selectively-targeted somatostatin receptor type 2 nonpeptide (SST2) agonist, is now the first once-daily, oral treatment approved for adults with acromegaly.
• The approval is based on data from the PATHFNDR-1 and PATHFNDR-2 Phase 3 pivotal trials, which evaluated PALSONIFY's safety and efficacy in previously treated and medically untreated adults with acromegaly.
• Across both trials, PALSONIFY consistently demonstrated rapid onset, reliable biochemical control, and sustained efficacy, along with significant reductions in signs and symptoms associated with acromegaly as measured by the Acromegaly Symptom Diary (ASD).
• PALSONIFY was generally well-tolerated, with no serious adverse events reported in the randomized controlled portion of the trial.
• Long-term results from the open-label extension (OLE) phases of both trials, presented at ENDO 2025, provided further evidence of durable IGF-1 control, sustained improvements in patient symptom burden, and a consistent safety profile, with 91% of patients from PATHFNDR-1 and 97% of completers from PATHFNDR-2 enrolling in the OLE.
• PALSONIFY is expected to be available in the U.S. in early October.
• Crinetics has launched CrinetiCARE, a comprehensive support program offering disease and product education, benefit verification, financial assistance, and access to dedicated nurse educators.

Sentiment

Score: 9

Explanation: The FDA approval of a first-in-class, once-daily oral treatment for acromegaly is a major positive milestone for Crinetics, validating its development pipeline and opening a significant commercial opportunity. The strong clinical trial data and patient-centric approach further enhance the positive outlook.

Positives

• Received FDA approval for PALSONIFY (paltusotine) for the first-line treatment of adults with acromegaly.
• PALSONIFY is the first once-daily, oral treatment approved for adults with acromegaly, addressing a significant unmet need for a convenient therapeutic option.
• Approval is supported by robust data from two pivotal Phase 3 trials (PATHFNDR-1 and PATHFNDR-2) demonstrating rapid, durable, and consistent biochemical control and reduced symptom burden.
• PALSONIFY was generally well-tolerated in clinical trials, with no serious adverse events reported in the randomized controlled portion.
• Long-term open-label extension data confirmed durable IGF-1 control, sustained symptom improvements, and a consistent safety profile.
• The launch of CrinetiCARE, a comprehensive patient support program, demonstrates a commitment to broad patient access and adherence.
• This approval marks a pivotal milestone for Crinetics, establishing it as a premier endocrine-focused global pharmaceutical company and validating its deep pipeline of small molecule drugs.

Negatives

• Potential adverse reactions include diarrhea, abdominal pain, nausea, decreased appetite, sinus bradycardia, hyperglycemia, palpitations, and gastroenteritis.
• Warnings and precautions include risks of cholelithiasis and its complications, hyperglycemia and hypoglycemia, cardiovascular abnormalities, thyroid function abnormalities, steatorrhea and malabsorption of dietary fats, and Vitamin B12 deficiency.
• Drug interactions with strong or moderate CYP3A4 inducers and proton pump inhibitors may require increased PALSONIFY dosage, and concomitant use of proton pump inhibitors should be avoided in patients already on PALSONIFY 60 mg.
• Cyclosporine exposure may decrease, requiring dosage adjustment and therapeutic monitoring when used with PALSONIFY.

Risks

• Data reported may change following completion or a more comprehensive review of clinical study data, and regulatory authorities may not agree with the interpretation of such results.
• Inability to obtain, maintain, and enforce patents and other intellectual property rights, or the prohibitive difficulty or cost to protect such rights.
• Geopolitical events may disrupt Crinetics' business, including delaying or otherwise disrupting clinical and preclinical studies, manufacturing, and supply chain, or impairing employee productivity.
• Unexpected adverse side effects, complications, and/or drug interactions or inadequate efficacy of product candidates may limit their development, regulatory approval, and/or commercialization.
• Dependence on third parties in connection with product manufacturing, research, and preclinical and clinical testing.
• Clinical and preclinical studies may not proceed at the time or in the manner expected, or at all.
• The timing and outcome of research, development, and regulatory review is uncertain, and drug candidates may not advance in development or be approved for marketing.
• Capital resources may be used sooner than expected, or the cash burn rate may accelerate.
• Future impacts to the business resulting from geopolitical developments outside the company's control.
• Other risks and uncertainties described in the company's periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024.

Future Outlook

PALSONIFY is expected to be available in the U.S. in early October. A Marketing Authorization Application (MAA) for paltusotine in acromegaly is currently under review for use in the European Union, with the Committee for Medicinal Products and Human Use (CHMP) opinion anticipated in the first half of 2026. Crinetics is partnering with Sanwa Kagaku Kenkyuso (SKK) to develop and commercialize paltusotine for acromegaly in Japan. Paltusotine is also being evaluated for the treatment of carcinoid syndrome in the pivotal Phase 3 CAREFNDR trial. The company's pipeline includes late-stage investigational candidate atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and over 10 additional discovery programs targeting various endocrine conditions and GPCR-targeted oncology indications.

Management Comments

• "With the FDA approval of our lead therapy Palsonify, today marks a new era for those living with acromegaly and also for Crinetics as a company. We are very pleased to be fulfilling our commitment to transforming patient lives. This approval is the first to come from our deep pipeline of first-in-class, small molecule drugs. This would not be possible without the help and partnership of people living with acromegaly, their caretakers, our employees, and the clinical researchers and health care professionals who contributed to Palsonify's successful development program. Thank you to all involved." Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics.
• "The PATHFNDR clinical development program set a new standard for acromegaly treatment by demonstrating the ability of Palsonify to drive both biochemical and symptom control, regardless of the degree of underlying disease severity. The approval of Palsonify is a significant advancement for our patients, as there is an unmet need for an easy-to-administer and safe therapeutic option with a rapid action and durable response that can consistently manage acromegaly." Dr. Shlomo Melmed, Executive Vice President of Medicine and Health Sciences and Dean of the Medical Faculty at Cedars-Sinai.
• "For people living with acromegaly, treatment once meant burdensome injections, breakthrough symptoms, and lifestyle sacrifices just to stay on track. What matters most to our community – maintaining consistent control so the disease doesn't control us – led us to partner with the FDA on Externally Led Patient-Focused Drug Development meetings. This new treatment reflects that our voices have been heard in shaping the next generation of acromegaly care." Jill Sisco, President of Acromegaly Community.

Industry Context

This FDA approval of PALSONIFY introduces a novel, first-in-class oral treatment for acromegaly, marking a significant advancement in a therapeutic area traditionally dominated by injectable somatostatin analogs. It addresses a critical unmet need for a convenient, once-daily oral option, potentially shifting the treatment paradigm and offering a substantial competitive advantage over existing therapies. The emphasis on patient-reported outcomes (Acromegaly Symptom Diary) also aligns with a broader industry trend towards patient-centric drug development and measuring real-world impact on quality of life.

Comparison to Industry Standards

• PALSONIFY is the first once-daily, oral treatment approved by the FDA for adults with acromegaly, setting a new standard compared to existing injectable somatostatin analog therapies.
• The PATHFNDR clinical development program demonstrated PALSONIFY's ability to drive both biochemical and symptom control, regardless of underlying disease severity, addressing an unmet need for an easy-to-administer, safe, rapid-acting, and durable therapeutic option.
• The development program incorporated the Acromegaly Symptom Diary (ASD), an FDA-aligned patient-reported outcome tool, reflecting a patient-centric approach to measuring treatment efficacy beyond just biochemical markers, which is a progressive standard in drug development.

Stakeholder Impact

• Shareholders: Highly positive impact due to a significant regulatory milestone, potential for increased revenue and market share, and validation of the company's drug development capabilities.
• Patients (Acromegaly): Highly positive impact with the availability of the first once-daily, oral treatment, offering greater convenience, improved quality of life, and effective symptom and biochemical control compared to injectable therapies.
• Healthcare Providers: Provides a new, effective, and convenient treatment option for managing acromegaly patients, potentially simplifying treatment regimens and improving patient adherence.
• Employees: Positive impact from the successful approval and commercial launch of a lead product, reinforcing the company's mission and potential for growth and stability.
• Payers: Crinetics is actively working with payers to ensure broad access, indicating ongoing discussions and efforts to secure coverage and reimbursement for PALSONIFY.

Next Steps

• Host an investor conference call on September 25, 2025, at 6:00 pm Eastern Time to discuss the FDA approval of PALSONIFY.
• Make PALSONIFY available in the U.S. in early October.
• Continue the review process for the Marketing Authorization Application (MAA) for paltusotine in the European Union, with a CHMP opinion expected in the first half of 2026.
• Proceed with the partnership with Sanwa Kagaku Kenkyuso (SKK) to develop and commercialize paltusotine for acromegaly in Japan.
• Continue the pivotal Phase 3 CAREFNDR trial for paltusotine in carcinoid syndrome.
• Advance late-stage investigational candidate atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.
• Further develop additional discovery programs targeting various endocrine conditions and GPCR-targeted oncology indications.

Key Dates

Recommendation

The FDA approval of PALSONIFY represents a transformative event for Crinetics Pharmaceuticals. As the first once-daily, oral treatment for acromegaly, it addresses a significant unmet medical need and offers a substantial competitive advantage in a market previously dominated by injectable therapies. The robust Phase 3 data, demonstrating rapid and durable biochemical and symptom control with a favorable safety profile, underpins strong commercial potential. This milestone validates the company's R&D capabilities and pipeline, positioning Crinetics for significant revenue growth and market penetration. The launch of a comprehensive patient support program further enhances its market readiness. Given the novelty, efficacy, and convenience of PALSONIFY, this approval is a strong catalyst for long-term value creation.

Keywords

Crinetics Pharmaceuticals, PALSONIFY, paltusotine, FDA approval, acromegaly, somatostatin receptor agonist, SST2 agonist, endocrine disease, pharmaceutical, biotechnology, clinical trials, PATHFNDR, oral treatment